HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Impetigo contagiosa III. Comparative efficacy of oral erythromycin and topical mupirocin.

Abstract
Ninety-seven patients with impetigo were prospectively enrolled in a study to determine the comparative efficacy of systemic and topical antibiotic therapy. After obtaining a bacterial culture from a representative lesion, the children were randomized to receive seven days of either oral erythromycin or topical mupirocin administered three times daily. Staphylococcus aureus alone was isolated from 51% and in association with group A beta-hemolytic streptococci (GABS) from 29%; GABS alone was isolated from 4% of patients. Of 48 children who received erythromycin, 43 (90%) were clinically improved or cured, and 11 of 17 were bacteriologically cured. Of 49 children who received mupirocin, 47 (96%) were clinically improved or cured, and 10 of 14 were bacteriologically cured. At three-week follow-up, clinical cure rates and number of secondary household cases of impetigo were equivalent in both treatment groups. Mupirocin appears to be a well-tolerated, albeit expensive, alternative to erythromycin for the treatment of impetigo.
AuthorsL L Barton, A D Friedman, A M Sharkey, D J Schneller, E M Swierkosz
JournalPediatric dermatology (Pediatr Dermatol) Vol. 6 Issue 2 Pg. 134-8 (Jun 1989) ISSN: 0736-8046 [Print] United States
PMID2501775 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Anti-Bacterial Agents
  • Fatty Acids
  • Erythromycin
  • Mupirocin
Topics
  • Administration, Oral
  • Administration, Topical
  • Adolescent
  • Anti-Bacterial Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Drug Resistance, Microbial
  • Erythromycin (administration & dosage, adverse effects, metabolism, therapeutic use)
  • Fatty Acids (administration & dosage, adverse effects, metabolism, therapeutic use)
  • Female
  • Humans
  • Impetigo (drug therapy, pathology)
  • Infant
  • Male
  • Mupirocin
  • Prospective Studies
  • Random Allocation
  • Staphylococcus aureus (isolation & purification)
  • Streptococcus (isolation & purification)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: